Get started

Biotechnology

Catalyst investing with T2 Biosystems (TTOO)Shares of T2 Biosystems (TTOO) have fallen by roughly 75% since the company's IPO was priced at $11 in 2014. Over the past 3 years, the share price has lost roughly two-thirds of its value and so far 2019 has seen further decline. Technical argument Limited: it’s no easy task trying to evaluate identify trading opportunities in price trends and patterns seen in small market capitalisation biotechnology. TTOO stock price is volatile because it is in possession of a breakthrough technology with its success relying on pivotal data that has not yet been made public. In addition, concerns remain, including cash burn and near-term financing. Even if TTOO is successful in achieving approval for various products the company may have difficulty getting hospitals and labs to adopt the technology. I have included indictors such as MACD, momentum, Moving Average MA, Relative Strength Index RSI and Point of Control POC. The conclusions from these indicators are limited, I have explained each individually on the graph. What I do draw from the graph is that TTOO has fallen back into the Point of Control: price point with the highest trade volume. We can see a bullish RSI divergence: TTOO makes a lower low and RSI forms a higher low and volume has started to increase. If investors consider the stock to be oversold the volume with continue to increase as traders buy stock and we will see a price rise. I would NOT buy stock based on this analysis because the volume spike could be investors offloading stock, even if we are at an all-time low. So let’s ignore the technical analysis because in this situation making an investment decision based solely on evaluating price trends won’t have any bearing on the outcome of upcoming catalysts and therefore the stocks potential value. Upcoming catalysts The company is in possession of a breakthrough technology for the detection of sepsis. A possible near-term catalyst for upside is results of the T2Bacteria Panel pivotal FDA clinical trial to be published in a peer-reviewed medical journal in Q2 2019 T2Lyme Panel is currently in a pivotal Phase 3 trial with very encouraging results so far and a $700 million market being targeted.
TLong
by warrenhochfeld
A Life Changing Science And A Life Changing StockSummary PKTX is where CSBR was 3 years ago. PKTX's AAGP molecule is life changing. Data is coming. With that comes higher stock price. Those of you who have been following me the last few years, because of my call on Champions Oncology, CSBR, know that I have been predicting that ProtoKinetix PKTX is destined to be my next CSBR. The dynamics of each company and their respective stocks have parallels that can not go unnoticed. For years CSBR had an incredible technology that the market had just not taken notice of. In 2014, 2015 and much of 2016 CSBR essentially traded by appointment and posted many zero volume days. Even a reverse split and an uplist to NASDAQ didn’t wake the stock up. Then around the 3rd quarter of 2016, the market finally took notice and we saw CSBR go from the high 1-dollar range to as high as $15 and some days trading several millions of dollars in volume. Why the big difference? Sure, they had some wins, they raised some money, landed a contract, increased revenues and brought on an IR firm, but at the end of the day, what really happened is, the market finally realized what they were all about. The market is not always efficient. Many great companies go unnoticed for years while many companies that are garbage enjoy the benefit of liquidity and over inflated market caps…dot com bubble, cryptocurrency, tulip bulb mania etc. First, a little bit about ProtoKinetix. OTCQB:PKTX. ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. For those of you that are not biochemists or hold a PHD in immunology, let me simplify what this means. Very simply put, their AAGP molecule: Is an anti-aging molecule Increases cell survivability Encourages cell growth Increases cell viability Improves cell functionality Why is this important? Because the use of the AAGP molecule can be used to improve treatments of nearly every disease known to man. I know…that’s a big deal. They began their first human trials in 2017. The trial is for the treatment of Type 1 diabetes with pancreatic islet transplants. The addition of AAGP to the transplant should increase the life of the islet, thereby increasing the success of the transplant. AAGP is currently being tested or soon to be tested in the following: Kidney Ischemia Ischemia is a condition that occurs when blood flow to cells, tissues or organs is severely restricted. This condition can affect any part of the human body. When this happens, cell death and organ damage follows rapidly. Ischemia is a major cause of kidney damage, heart attacks and strokes. Testing will determine whether AAGP™ can reduce the inflammatory response that causes cell damage and organ failure that occurs during an ischemic attack. Normothermic Liver Perfusion Normothermic (body temperature), ex vivo (outside the body) liver perfusion (method of irrigation) is a therapy to livers outside of the body before transplantation. Again, simply put, AAGP, will keep the harvested organ viable longer. This can apply to any organ of the body. A true game changer for organ transplants. Retinal Cell Replacement Use of AAGP will improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. Studies have already been completed at the University of British Columbia and showed dramatic improvement on cell survivability and viability, functionality with the addition of AAGP. Monoclonal Antibody Production Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell, these are used in the rapidly growing field of immunotherapy. Monoclonal antibodies are currently being used to treat Cancer, Rheumatoid Arthritis, Multiple Sclerosis, Cardiovascular Disease, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Psoriasis, Transplant Rejection, and several more conditions. By adding AAGP will lead to a dramatic decrease in the cost of production of monoclonal antibody medicines. Bone Marrow Recovery Bone marrow can be collected and cryopreserved. Conditions that can be treated by transplantation include bone marrow diseases, histiocytic disorders, hemoglobin opathies, inherited immune system disorders, inherited metabolic disorders, leukemias and lymphomas, myelodysplastic syndromes, multiple myeloma, plasma cell disorders, other cancers and malignant diseases. The inclusion of AAGP will increase functionality and viability of the bone marrow. This could then be expanded to all cryopreserved cells. Cord Blood Preservation Cord blood is the blood left in the umbilical cord and placenta immediately after birth. It can be collected, stored and used at any time during a baby’s lifetime to treat a wide variety of diseases and medical conditions. Cord blood is currently being used to treat multiple forms of cancer, hematopoietic diseases, inborn errors of metabolism and immune system diseases. You guessed it, AAGP will improve viability and function of the stored cord blood cells. Ischemic Stroke Repair Ischemic Stroke is associated with severe disabilities and a high recurrence rate. Testing of AAGP™ molecule is to prove it suppresses the inflammatory attack caused by ischemic stroke thereby preventing any long-term damage to the human body. I could continue but I think that I’ve made my point. AAGP part of the future for the treatment of cancer, blindness, diabetes, transplants, stroke… AAGP conceivably could be used in every cutting edge treatment that we are currently aware of. We’re not just talking about one of two things it can treat, as stated before we are truly talking about nearly every ailment that affects the human body. To be clear, these things are currently in trials and studies, but the results have been nothing but positive. Last year they announced their first working relationship with a large unnamed international biotech company. I believe we will see more of this. Given the enormity of the possibilities of this molecule, I see only one outcome for ProtoKinetix and that is a sell of the company. They are just too small to capitalize on such a vast technology. Now that I’ve covered the science and its potential, let’s get into the nuts and bolts of the company. The company was essentially left for dead in 2012. No filings were made for over 18 months and the demise of the company was a given. Then in 2014, through the efforts of the current CEO, the company was revived. This is not the typically outcome for a micro-cap that is in trouble. By mid-2014, the company was current of their filings and back up and running. They also moved from Canada to the US. Not only did they get going again, they are one of the tightest ran micro caps you will find. The 2018 cash burn for the company was just under $600k. This is remarkable for any public company but even more so for a biotech. In part they are able to keep expenses low due to the fact that most of their trials and studies are Investigator Sponsored by the University of Alberta, so the company isn't the one footing the bill for the research. Another reason for the low expense is the CEO’s salary is $1 a year. More on him later. To top it all off the company not only has no convertible debt it has no debt at all. Unheard of for a small biotech. One last compelling thing about this company is the amount of insider buying. I can safely say; I have never seen as many Form 4’s from a company as I have seen from PKTX. The buying has been significant. To give you an idea, the current CEO’s initial form 3 that was filed in June of 2014, showed him owning 19,670,500 shares. His most recent form 4 shows him owning 61,353,833 shares. I’ll save you the math exercise, that is an increase of over 41 million shares. Some have been acquired through private placements, but a huge number have been bought in the open market. The past and current CFO were and are regular Form 4 filers as well. So, the big question? Why is PKTX only trading at .08 with a $22 million market cap. There are a few reasons. Like CSBR, they have been spending their time on building a business and increasing the value of their technology, rather than spending their time on pumping their stock up. History. Like I said, the stock was left for dead and forgotten about. It takes a long time to recover from that. And legacy shareholders, I’m sure took advantage of an opportunity to get out, once they had the chance. It’s a tough environment for OTC stocks. In a market that has been as good as what we’ve seen the last few years, people are content with the easy money being made in the big names. Why buy now? The technology…AAGP is a life changing molecule. Nearly unlimited upside. Last year’s announcement of a Material Transfer Agreement with a global biotech company. Although the market didn’t take much notice, this is significant. It’s official, the big boys are starting to explore the AAGP molecule. Data/Trials/Studies – Press this week announced they expect results from Phase 3 testing for Retinal Cell Replacement. Data is king and we’re starting to get it. Data is what will bring big biotech knocking…along with their checkbook. No debt Insider buying It’s cheap. $22 million market cap is nothing for a company with a technology of this potential. I do believe the time is now. ProtoKinetix not only has a life changing molecule, I’m also betting that PTKX will be a life changing stock. Disclosure: I am/we are long PKTX, CSBR.
OTC:PKTXLong
by battlestsr01
Bottom in the making (ONXEO SA)The price is at the lowest area since its listing on OMXC. The price have been down with 90 %. RSI combined with price shows (look at the red arrows at RSI) that while price is making Lower lows, the RSI is makin Lower highs, which shows that strength of sellers is weakned. This is typical sign of bottom is about to be made. 4H technical shows a bearish 20-50 cross accured which will push the price a bit lower than now. That is why trade is active at price 6.5. Stoploss is set at 7 % below the lowest price, and also a bit below a triangle, in case of stop hunting. 1st profit taking zone is 0.5 fib zone, if this upper movement is correction. There is a huge gap, which I think will be closed, sooner or later, which is why the 3rd profit taking zone is where the gap is closed. A trade with good R:R.
OLong
by fehimsahan
CELLECTIS LONG TERM BUYHi Guys Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin. TA: - Double bottom which is normally an indicator for a reversal. - higher high and higher low - Oversold Stoch RSI (4hr) - Rising MACD Fundamentals: - CASH POSITION OF $ 452M AS OF DECEMBER 31, 2018 COMPARED TO $ 297M AS OF DECEMBER 31, 2017 - CELLECTIS, THROUGH ITS NEW SUBSIDIARY CELLECTIS BIOLOGICS, INC., ENTERED INTO A LEASE AGREEMENT TO BUILD A MANUFACTURING FACILITY IN NORTH CAROLINA, ADVANCING COMMERCIALIZATION CAPABILITIES FOR ITS UCART PORTFOLIO - UCART123 IN PHASE 1 DOSE ESCALATION CLINICAL TRIAL ONGOING FOR AML - UCART22 RECEIVED FDA AND IRB APPROVALS FOR PHASE 1 DOSE ESCALATION CLINICAL TRIAL IN B-ALL PATIENTS - UCART19 ASH ABSTRACT BY PARTNERS SERVIER AND ALLOGENE SHOWED CONTINUED PROGRESS OF FIRST CLINICAL ALLOGENEIC CAR T-CELL PROGRAM FOR ALL ADULT AND PEDIATRIC PATIENTS. MILESTONES PAYMENT CONTRACT WITH PFIZER AND SERVIER UPCOMING CHECK OUT ALSO THIS AMAZING STORY. WE'RE ABOUT TO CHANCE THE FUTURE BUT ITS A LONG WAY TO GO google: layla cellectis
NASDAQ:CLLSLong
by don_padrone
Biotech symmetry. Let the market settle down, and then go long.The biotech sector is really interesting when you dive down into the symmetry of the last few cycles. Early 2000s-2008 and 2016-2018 are mini rallies within the bigger wedge. If this pattern is to continues, you can look for entry around the end of 2020 when we bump up against the larger support line (around $3600), and expect to hit the resistance of the larger wedge ($10,000). There is also a lot of confluence around the $7500 mark so we could fall back to that after hitting 10k. This would repeat this pattern for the third time. Near term, I have some shorts in this sector because I think many of this small biotech companies have been operating at negative cash flow with a ton of free credit. I don't expect massive gains on these shorts, but I will certainly be going long towards the end of 2020.
NYSE:BTKLong
by warrenbudget
Loxo - Bull pennant and upcoming eventsThis is the weekly chart on Loxo Oncology. This biotech focuses on cancer treatments by targeting genetic mutations that create protein chimers that lead to unregulated cellular proliferation. In English, and very simply, imagine a copy machine. When you press 'Copy' you should get one duplicate of the item you want copied. Cells have similar systems where a protein in the cell membrane receives a signal from the outside world telling the cell to divide and make a copy of itself. Now imagine your copy machine crosses circuits with a 'Repeat' button. This will lead to infinite, unchecked copying. In cancer a similar thing occurs. Genetic mutations can cause the growth signalling protein to get joined to other proteins leading to unchecked, infinite cellular proliferation. This is one of the several steps to developing cancer. Loxo has developed and is testing drugs that target these specific mutations. Their leading drug, Lorotrectinib, targets TRK fusion proteins (-tinib as a suffix indicates it inhibits tyrosine kinases) and has shown good efficacy in combating several types of cancer with minimal side effects reported. Notable upcoming events are a data review at an upcoming oncology conference October 19-23, Earnings Report on 11/5/18, and a New Drug Application review PDUFA by the FDA on 11/26/2018. The last date is the most important as Loxo could see Lorotrectinib obtain FDA approval. Other possibilities for the PDUFA are an extension of the review or rejection of the drug. From the research reports I have read so far on Lorotrectinib I am doubtful a rejection/denial will happen. I suspect it will either be approved or the review extended and this will depend upon new data, likely to be presented in October. The chart currently looks bullish to me. There is a clear uptrend long term with us likely in a Wave 2 in Elliot Wave Theory. Mid term price is consolidating in a descending wedge/bull pennant. The safe trade is to buy once price breaks the top of the channel. An aggressive option is to buy when price touches the bottom of the channel. If I buy prior to earnings I will probably trim half my position the day before ER then play the run up to the PDUFA review late November. ***This is not investing advice. I am not an investing professional. Do not invest what you cannot afford to lose. All investors should seek guidance from licensed financial advisers and not random people on the internet.***
LLong
by ruud_one
BLRX-BREAKOUT-UPDATEBLRX had a strong rally today and it's just getting started. In the related idea my price target was $1.34. Today's high was $1.78 Check out the weekly chart: Photo Finish. $1.34 was 1.618 extension level from Waves 1 & 2. Since the price-action broke $1.34 we will have an extended 3rd wave. I expect a very strong rally tomorrow, I will update in the morning before the open to confirm. Target is hard to predict since its impossible to know what level extending waves will terminate. I will keep a close eye on the price-action. Will update. -AB
NASDAQ:BLRXLong
by FibMarketWatch
BLRX - BioLine RX - Promising Biotech with Big upside - LongBLRX BL-8040 Overview BL-8040 is a novel, short peptide that functions as a high-affinity antagonist for CXCR4, which BioLineRx is developing for the treatment of solid tumors, acute myeloid leukemia, or AML, and stem-cell mobilization for bone-marrow transplantation. Solid Tumors: In January 2016, BioLineRx entered into a collaboration with MSD, known as Merck in the U.S. and Canada, in the field of cancer immunotherapy. Based on this collaboration, in September 2016 BioLineRx initiated a Phase 2a study, known as the COMBAT study, focusing on evaluating the safety and efficacy of BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in up to 30 patients with metastatic pancreatic adenocarcinoma. The study is an open-label, multicenter, single-arm trial designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. Partial results will be presented at the 2018 ASCO Gastrointestinal Cancers Symposium (ASCO GI) in January 2018, with top-line results expected in the second half of 2018. September 2016, BioLineRx entered into a collaboration with Genentech , Inc., a member of the Roche Group , in the framework of which both companies would carry out Phase 1b/2 studies investigating BL-8040 in combination with atezolizumab (TECENTRIQ®), Genentech’s anti-PDL1 cancer immunotherapy, in various solid tumors and hematologic malignancies. Genentech commenced a Phase 1b/2 study for the treatment of pancreatic cancer in July 2017, as well as a Phase 1b/2 study in gastric cancer in October 2017. Genentech expects to commence an additional Phase 1b/2 study in lung cancer by early 2018. In September 2017, BioLineRx initiated a Phase 1b/2 study under this collaboration in acute myeloid leukemia (AML). These studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters. n March 2015, BioLineRx reported successful top-line safety and efficacy results from a Phase 1 safety and efficacy trial for the use of BL-8040 as a novel stem-cell mobilization treatment for allogeneic bone marrow transplantation at Hadassah Medical Center in Jerusalem. In March 2016, BioLineRx initiated a Phase 2 trial for BL-8040 for allogeneic stem-cell transplantation, conducted in collaboration with the Washington University School of Medicine, Division of Oncology and Hematology. Initial results of this study announced in March 2017 show that a single injection of BL-8040 mobilized sufficient amounts of cells required for transplantation at a level of efficacy similar to that achieved by using 4-6 injections of G-CSF, the current standard of care. Topline results of this study are now expected in mid-2018, as a result of certain delays in study recruitment in connection with the addition of two sites to the study and the regulatory filings associated therewith. In August 2017, following a successful meeting with the FDA , BioLineRx announced the filing of regulatory submissions required to commence a randomized, controlled Phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells, or HSCs, for autologous transplantation in patients with multiple myeloma. The trial is expected to commence by the end of 2017. In November 2017, BioLineRx disclosed preclinical data supporting BL-8040 as robust mobilizer of hematopoietic stem cells, or HSCs, associated with long-term engraftment. The data will be presented as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, GA, taking place in December 2017. Pre-Clinical Data In vitro and in vivo data show that BL-8040 binds to CXCR4 at the low nanomolar range (1-10nM) and occupies it for prolonged periods of time (>24h). Characterization of the CXCR4 antagonism action of BL-8040 in comparison to other CXCR4 antagonists revealed that, unlike other compounds from the same class, BL-8040 acts as an antagonist as well as an inverse agonist. This activity leads to decreased autonomous signaling of CXCR4 and suggests activity against constitutively active variants. BL-8040 inhibits the growth of various tumor types including multiple myeloma, non-Hodgkin’s lymphoma, leukemia, non-small cell lung carcinoma, neuroblastoma and melanoma. BL-8040 significantly and preferentially stimulated apoptotic cell death of malignant cells (multiple myeloma, non-Hodgkin’s lymphoma and leukemias). Significant synergistic and/or additive tumor cell killing activity has been observed in-vitro and in-vivo when tumor cells were treated with BL-8040 together with Rituximab, Bortezomib, Imatinib, Cytarbine, BCL-2 inhibitor ABT-199 and the FLT-3 inhibitor AC-220 (in NHL, MM, CML, AML, and AML-FLT3-ITD models, respectively). BL-8040 also mobilizes cancer cells as well as neutrophils and progenitor cells from the bone marrow to the peripheral blood. The U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to BL-8040 as a therapeutic for the treatment of AML as well as for stem cell mobilization BL-8040 is being developed by BioLineRx under a worldwide, exclusive license from Biokine Therapeutics. 1. Conclusion: The current data demonstrate that BL-8040 induces mobilization of AML blasts from the BM and has sustained receptor occupancy. In addition, a direct effect on AML blast viability has been observed in samples obtained during BL-8040 monotherapy. Importantly, the data suggest a differential effect of BL-8040 monotherapy on AML blasts vs. normal progenitors. BL-8040 was found to be safe and well tolerated at all doses tested to date. The updated results of the dose escalation phase of this ongoing study will be presented. Source: www.bloodjournal.org 2. The FDA approved the first immunotherapy drug recently, but the field dates back to 1891, when William Coley, a physician and cancer researcher, observed that some cancer patients infected by Streptococcus bacteria experienced a dramatic and spontaneous improvement. He began injecting the bacteria into his patients, with mixed results. The treatment was nearly abandoned amid skepticism from Coley’s peers and the advent of radiotherapy and improved surgical techniques. Today, however, new avenues of immunotherapy research are underway, and the field is considered among the most promising new approaches to cancer treatment, according to Jill O’Donnell-Tormey, CEO and director of scientific affairs at CRI. Source: www.jta.org 3. "activated with human interleukin 2, or activated against patients own tumor cells in the laboratory, when such are available – have been extremely successful in killing every last cancer cell in the patients. The theory is the same, in that the cells are trained to act as honing devices." “It’s fantastic because they all were expected to have been dead long ago,” Slavin told ISRAEL21c. “When the laboratory-treated and separated NK cells are infused into a patient, they go immediately to work because they were already trained in the laboratory to become professional killer cells capable of recognizing and destroying foreign cells.” "The new procedure has little or no side effects, is done during fifteen-minute outpatient intravenous infusion and has already showed promising results in high risk patients with metastatic or resistant cancer." "In order for the procedure to be government-approved, a much larger number of patients must successfully undergo treatment." "The reason I am optimistic is because we use mother nature’s tool – immune-system-cells to fight off disease. Normally too, it is the immune system that can recognize cancer cells as undesirable, and under normal circumstances, it will go on an attack until the single abnormal cell, which can grow to a bitter enemy, is gone. In patients with cancer, the patient’s own immune system failed to recognize the enemy and this is why we use the immune system cells from another individual that can easily recognize and destroy such tumor cells escaping the attention of patient’s immune system,” said Slavin." Summary Source: seekingalpha.com In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents. New oncology asset AGI-134 induced complete tumor regression in 50% and 67% of two mice melanoma preclinical studies. The company plans to start Phase 1/2a clinical trials in 1H 2018. BiolineRx is funded to 2020 with $55M in cash, no debt. However cash balance might be higher since it's likely company was selling against a $30M ATM since November. The company has plans to deliver up to a dozen high-potential catalysts in 2018 following a busy January (4 conferences, and 4 clinical data). Institutional ownership has increased from 20% to almost 60% in a year. Five analysts have a consensus Buy rating with $3.5/share price target. Chart Screenshots: screenshots.firefox.com screenshots.firefox.com screenshots.firefox.com Will update. -AB
NASDAQ:BLRXLong
by FibMarketWatch
ENDP - SHORT-TERM SHORT & LONG-TERM BUY - Endo Pharma ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. The Crash: Revenue Is In Free Fall Endo Pharmaceuticals: The Free Fall Continues Mar. 26, 2018 Summary Revenue from ENDP's core Generics business is in decline and other business segments appear in disarray. Its $8B debt load is at 7.5x run-rate EBITDA. If operating income continues to slide, it could hurt ENDP's ability to service its debt. ENDP ENDP trades at 9x EBITDA, but it is uncertain if potential legal exposures pursuant to opioids are priced in. Sell ENDP. This idea was discussed in more depth with members of my private investing community, Shocking The Street. There is a war being fought over drug prices. Lawmakers have hit back at price gougers and opioid manufacturers, and Endo Pharmaceuticals (ENDP) is in the middle of it. A few months ago, I thought Endo was at an inflection point and there was a good probability it could turn things around. However, its slide continues. What: The bottom dropped out from under shares of Endo International plc (NASDAQ:ENDP), the specialty pharma famous for selling "uncrushable" opioids and agreeing to enormous legal settlements. After management revealed disturbing revisions of its 2016 full-year estimates, the stock plummeted 41.4% last month, according to data from S&P Global Market Intelligence. Logical? Sold because they sell opiates? Are opiated still needed/critical to US Healthcare? NO! BIG Consolidation period: 4 Years (2014-2018) The First CYCLE WAVE Completed. Now, in the middle of the SECOND WAVE (Correction) Key Levels for Retrace: 1, 1.382, & 1.618 Look for retrace back to around $13.00 ENDP screenshots.firefox.com screenshots.firefox.com screenshots.firefox.com Most Recent News: Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Analysts at RBC Capital upgraded Endo International PLC (NASDAQ:ENDP) from Sector Perform to Outperform. Endo shares rose 2.56 percent to $16.05 in pre-market trading. Will update. -Stay humble America, -AB
ELong
by FibMarketWatch